Bespoke Pan Cancer (Natera)
Brief Summary:
This is a prospective, multi-center, single arm study designed to collect data to clinically characterize biomarkers associated with Natera test(s) from participants diagnosed with Stage I to IV tumors, for whom standard of care Natera MRD testing has been ordered (such as SignateraTM, SignateraTM Genome, or LatitudeTM). Data collection will occur annually for up to five (5) years.
Study Title:
Bespoke Pan Cancer
Conditions:
Stage I-IV Solid Tumor Cancer Patients Receiving Natera MRD Testing.
Pan‑tumor MRD Study
Brief Summary
The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back.
Official Title
Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers (NCT06605404)
Conditions
Esophageal Cancer , Melanoma (Skin Cancer),NSCLC (Non-small Cell Lung Cancer)